On December 16, 2021, CADTH provided an update regarding CADTH’s drug review programs.

A. Expanded Provisional Funding Algorithm Process

CADTH has expanded the provisional funding algorithm process to include a new rapid algorithm process. This rapid algorithm process will be applied when pERC recommendations can be directly inserted into an existing funding algorithm without needing additional advice from clinical specialists (e.g., when the new drug will not alter the current sequence of drugs within an existing funding algorithm).

Please consult the updated Procedures for CADTH Reimbursement Reviews for more information.

B. Implementation Advice for COVID-19 Drugs

CADTH has established a new process for the review of COVID-19 drugs. The purpose of these reviews is to provide implementation advice to the Provincial and Territorial Ministries of Health through an implementation advice report.

For more details, please consult the CADTH Pharmaceutical Reviews Update — Issue 27.

Please contact Ara Salazar, Director Project Management at ara.salazar@pdci.ca for any questions or further information.